# A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Source: https://onco.cc/trials/nct06521567/  
OnCo record `nct06521567` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cobolimab, Dostarlimab in melanoma and hodgkin lymphoma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer is a phase 1/2 interventional study registered as NCT06521567 by GlaxoSmithKline, with 83 participants planned, started 2025-03-06 and due to reach its primary completion in 2026-10-13. Interventions recorded: Cobolimab, Dostarlimab. Conditions listed: Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06521567
- Phase: 1/2
- Setting: Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
- Sponsor: GlaxoSmithKline
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT06521567: https://clinicaltrials.gov/study/NCT06521567

## Connected records

- cancers: [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/), [Ependymoma](https://onco.cc/cancers/ependymoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Cobolimab](https://onco.cc/drugs/cobolimab/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06521567.json